Sarah R Hosford

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

T. Miller, Sarah R. Hosford, Sarah R Hosford, 2014, Pharmacogenomics and personalized medicine.

The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer

G. Schwartz, Wei Yang, K. Shee, 2014, Breast Cancer Research and Treatment.

Autophagy promotes escape from phosphatidylinositol 3‐kinase inhibition in estrogen receptor‐positive breast cancer

E. Demidenko, Wei Yang, K. Shee, 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha–Positive, PIK3CA-Mutant Breast Cancer

A. Eastman, D. Bates, E. Demidenko, 2016, Clinical Cancer Research.

Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer

S. Bouley, E. Demidenko, Wei Yang, 2016, Clinical Cancer Research.

Estrogen therapy induces receptor-dependent DNA damage enhanced by PARP inhibition in ER+ breast cancer

E. Demidenko, Yaron Mosesson, G. Schwartz, 2023, bioRxiv.

High estrogen receptor alpha activation confers resistance to estrogen deprivation and is required for therapeutic response to estrogen in breast cancer

E. Demidenko, T. Miller, Nicole A. Traphagen, 2021, Oncogene.

Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer

E. Demidenko, A. Kettenbach, K. Shee, 2019, Molecular oncology.

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and Pi3K/AKT/mTOR pathways

Sarah R Hosford, Todd w Miller, 2014 .

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and Pi3K/AKT/mTOR pathways

Sarah R Hosford, Todd w Miller, 2014 .

Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways

T. Miller, Sarah R Hosford, 2014, Pharmacogenomics and personalized medicine.